131 results about "Monkeypox virus" patented technology

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The application relates to an antibody against monkeypox virus and a preparation method thereof, and the humanized monkeypox virus antibody H3-14A7 is obtained by screening memory B cells of a human antibody against H3 specific binding mouse. The H3-14A7 has the characteristics of strong monkeypox virus binding capacity, good in-vitro neutralization, large affinity and in-vivo protection.

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The invention discloses an application of Arcyriaflavin A or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating monkey pox virus infection. The invention finds that the Arcyriaflavin A can obviously inhibit the replication of the monkey pox virus in a Vero cell, and the IC50 of the Arcyriaflavin A for inhibiting the Ib branch monkey pox virus and the IC50 of the Arcyriaflavin A for inhibiting the IIb branch monkey pox virus are 0.66 mu M and 0.96 mu M respectively. The invention also verifies that the Arcyriaflavin A has extremely low toxicity to Vero cells, and the toxicity CC50 of the Arcyriaflavin A to the cells is 41.51 mu M when the Arcyriaflavin A is used for inhibiting the proliferation of the monkey pox virus, so that the Arcyriaflavin A can be used for effectively inhibiting the replication of the monkey pox virus within the safe use range of the Arcyriaflavin A. The invention provides a new choice for the prevention and treatment of monkey pox, and has important significance for the prevention and treatment of monkey pox.

This invention relates to monoclonal antibodies for detecting A35R protein and their applications. This invention screened six antibodies, including antibody 4E7, antibody 11G12, antibody 6F10, antibody 6C11, antibody 18C3, and antibody 23A7. Specifically, this invention discloses the amino acid sequences of the heavy chain variable region and the light chain variable region of the above antibodies, as well as the amino acid sequences of their complementarity-determining regions and framework regions. Antibodies 4E7 and 11G12 can bind not only to the A35R-MPXV protein but also to its homologs A35R-CPXV, A35R-VTT8, and A35R-Variola. Antibodies 6F10, 6C11, 23A7, and 18C3 can specifically recognize the A35R-MPXV protein. The monoclonal antibodies described above all exhibit high binding capacity to the A35R protein, making them suitable for the sensitive and specific detection and prevention of monkeypox virus A35R protein. They can also be used clinically for the diagnosis and treatment of monkeypox virus infection-related diseases.

Provided herein are methods of producing immunoglobulin Y (IgY) antibodies against monkeypox virus. The method includes immunizing hens with a peptide encoding at least one immunogenic domain of A29 fusion protein from the monkeypox virus and isolating the IgY antibodies against the A29 fusion protein from yolks of eggs laid by the immunized hens. Pharmaceutical compositions containing the IgY antibodies and methods of inhibiting or treating monkeypox virus infection are also provided.

This application discloses antibodies against monkeypox virus, their preparation methods, and applications. Specifically, this application discloses eight antibodies (A35R-9E4, A35R-9F8, A35R-10C4, A35R-10D5, A35R-10E7, A35R-10H6, A35R-18E2, and A35R-18H2) that have excellent affinity for the monkeypox virus A35R protein, and that they exhibit good neutralizing activity and certain in vivo protective effects.

The invention relates to the technical field of medicines, in particular to application of aspiramycin and / or imiquimod in preparation of a medicine for treating VACV. Aspiramycin and imiquimod which are screened from medicines on the market have antiviral activity, and experimental data show that the Aspiramycin and the imiquimod have anti-VACV medicine activity. Aspiramycin and imiquimod (especially combined application) are used for preparing the medicine for treating VACV, so that the time and cost of preclinical research can be greatly reduced. As the action mechanism of the pox viruses is not unique to the VACV, the combined strategy has the potential to be expanded to infection treatment of other pox viruses (such as monkey pox virus MPXV) and even other DNA (Deoxyribose Nucleic Acid) viruses.

The application belongs to the technical field of image recognition, and discloses a monkeypox virus classification method and system based on image comparison and a storage medium, which comprises an individual reference modeling module, collects normal skin and initial lesion images of a healthy side of a patient, generates a healthy texture template and an initial lesion reference library, performs gray scale normalization on the healthy texture template and the initial lesion reference library through adaptive histogram stretching, and outputs a comparison reference image group; a symptom density quantification module, acquires a current monitoring image of the patient, segments a lesion area in combination with the comparison reference image group, extracts layered features of the lesion area to generate a three-dimensional symptom density vector, extracts texture roughness of a surface of the lesion area, and constitutes a lesion quantification data set; the accuracy of disease monitoring is improved, and a clinical nursing process is optimized.

The present application relates to a kind of artificially synthesized recombinant monoclonal antibody with human antibody amino acid sequence as framework.The present application uses phage display technology, and obtains one monoclonal antibody H11 from Tomlinson I+J phage library, and these new amino acid sequences constitute CDR1, CDR2 and CDR3 region, can be combined with A29L protein specific binding.It shows good stability, high specificity and high affinity and other characteristics, provide tool support for subsequent monkeypox virus diagnosis and detection with A29L protein as target.

The invention relates to the field of antibody engineering, in particular to a monoclonal antibody specifically targeting a monkey pox virus and application of the monoclonal antibody. According to the invention, by screening mouse memory B cells specifically combined with monkey pox virus envelope protein A35R, monkey pox virus antibodies 1H4, 3H3, 3H6, 13H1 and 17H1 with high neutralization activity are obtained. Wherein 17H1 has excellent affinity and neutralizing efficacy on monkey pox virus and has a strong in-vivo protection effect, and 100% of survival rate of challenged mice is achieved in prevention and treatment experiments. The sequence of the antibody is completely different from that of an existing monkey pox virus antibody, and a new candidate product is provided for detection, diagnosis, prevention and treatment of the monkey pox virus.

Disclosed are an assay, method, and kit for detecting a monkeypox virus (MPXV) and the application thereof. The assay may be used alone or in combination with another assay or assays. The method of using and kit includes a composition used for detecting MPXV, wherein the composition is composed of a primer pair and a probe. The primer pair is composed of two single-stranded nucleic acid molecules shown in the first sequence and the second sequence in a sequence list, and the sequence of the probe is the third sequence in the sequence list. The kit is used for detecting MPXV, and has advantages of providing real-time screening of MPXV reducing cross-reaction to other pox diseases, and increasing specificity to MPXV for disease prevention and improvement of public health.

The invention belongs to the technical field of biology, and discloses an anti-monkey pox virus E8 antibody or an antigen binding fragment thereof and application thereof. The invention provides an anti-monkey pox virus E8 monoclonal antibody 2F6, 9G4, 9H1 or 10E11, which can specifically recognize and target orthopox viruses such as monkey pox, vaccinia and the like, and shows efficient virus neutralizing capacity. The clinical application value of preventing and treating orthopoxvirus infection is realized; the compound can be used for detecting orthopoxvirus, diagnosing diseases related to orthopoxvirus infection and preventing and / or treating orthopoxvirus infection and / or diseases related to orthopoxvirus infection.

The present application relates to the technical field of biotechnology, in particular to a monoclonal antibody against A29L protein of monkeypox virus and application thereof. The present application prepares the monoclonal antibody against A29L protein of monkeypox virus, and through optimization of antibody screening and expression technology, the antibody with high affinity and high specificity is screened, and then a new tool is provided for rapid detection, effective neutralization and treatment of monkeypox virus, and an important immunological basis is provided for vaccine research and development and treatment scheme design of monkeypox virus.

This invention discloses a high-throughput screening method for monkeypox virus (MPXV) N7-methyltransferase (N7-MTase) inhibitors based on fluorescence polarization technology and its application. This method uses MPXV E1... CTD Using the / E12 protein complex as a target, and leveraging the specific binding characteristic of the fluorescent probe FL-NAH to the target catalytic center, small molecule inhibitors that competitively bind to the SAM binding site are screened by monitoring changes in fluorescence polarization signals. This invention yielded a series of candidate compounds with significant inhibitory activity. Experiments demonstrated that these inhibitors exhibit strong inhibitory effects on MPXV N7-MTase, with a biochemical IC50 level of [missing information]. 50 Preferably, the concentration can reach 4.65 μM; at the cellular level, the compound exhibits a clear attenuation effect against poxviruses, with an EC50 value of [missing value]. 50 The range is up to 46.75 μM, and it has low cytotoxicity (CC). 50 >200 μM).

The present invention is directed to a method for detecting the presence or absence of monkeypox virus (MPXV) in a biological sample, the method comprising: a) contacting the sample or nucleic acid extracted from said sample with reagents and an oligonucleotide combination capable of amplifying a target region of a monkeypox viral genome, wherein said oligonucleotide combination is selected from the group consisting of: i) a B7R oligonucleotide primer set specific for amplifying a target sequence in the B7R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:65; and ii) a G2R oligonucleotide primer set specific for amplifying a target sequence in the G2R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:63; b) performing an in vitro nucleic acid amplification reaction, wherein any MPXV nucleic acid present in the sample is used as a template to generate the MPXV amplification product corresponding to the oligonucleotide combination of i) or ii); and c) detecting the presence or absence of the MPXV amplification product generated in step b), wherein the presence of the MPXV amplification product is indicative of the presence of MPXV in the biological sample. The present invention also provides oligonucleotides which can be used in the method of the invention as primers and probes.

The application provides a monkeypox virus typing kit, application and product in situ, and belongs to the technical field of molecular detection. The application first provides a monkeypox virus typing kit in situ, which comprises primer probe compositions for identifying monkeypox branch Ia type, branch Ib type and branch II type. The application further provides a combined kit comprising monkeypox identification primer probes or orthopoxvirus identification primer probes. The application achieves the effect of balanced amplification in the same amplification system through the combination optimization of the primer probes, accurately types the monkeypox virus at one time, and simultaneously realizes the identification of the monkeypox virus or the orthopoxvirus. The kit has the characteristics of high sensitivity and high accuracy, can reduce the interference of external substances, has strong stability, and has high practical application value.

The application discloses a crRNA target point and a CRISPR-Cas13a system for detecting monkeypox virus. The CRISPR-Cas13a system comprises a Cas13a protein and a crRNA, or a complex formed by both; the crRNA comprises an anchor sequence for being combined with the Cas13a protein and a guide sequence for targeting a monkeypox virus target point sequence; and the monkeypox virus target point sequence is located at the 46242-46703th position of a monkeypox virus genome. Experiments prove that the crRNA can realize high-sensitivity and high-specificity detection on the monkeypox virus nucleic acid by activating the Cas13a, and the sensitivity reaches 10 copies (10 copy / µL).

A disclosed lanthanide fluorescent antigen kit based on monkey pox virus detection comprises an antigen kit, the interior of the antigen kit is fixedly connected with a fixed placing frame, the top of the fixed placing frame is provided with two concave grooves, and each concave groove is internally provided with a plurality of antigen reagent sampling mechanisms; a clamping mechanism is arranged at a position opposite to the bottom end of the antigen reagent sampling mechanism; and an ejection mechanism is arranged at the bottom end of the clamping mechanism, the clamping mechanism comprises a clamping round frame fixedly connected with the bottom end of the interior of the concave groove, and a plurality of fixed rectangular shells are arranged at the top end of the interior of the clamping round frame. According to the scheme, a lanthanide fluorescent antigen reagent test tube for detecting the monkey pox virus is conveniently placed in a clamping round frame on the fluorescent antigen kit, and the lanthanide fluorescent antigen reagent test tube for detecting the monkey pox virus is extruded and clamped by a movable extrusion roller through telescopic matching of rectangular strips in a plurality of fixed rectangular shells.

The application discloses a fluorescent PCR kit for simultaneously detecting monkeypox and monkey B virus, and the kit comprises a primer mixture capable of simultaneously detecting monkeypox virus and monkey B virus, wherein the primer sequence for detecting the monkeypox virus is shown as SEQ ID No. 01 and SEQ ID No. 02; and the primer sequence for detecting the monkey B virus is shown as SEQ ID No. 03 and SEQ ID No. 04. The application further provides a method for simultaneously detecting monkeypox virus and monkey B virus by using the fluorescent PCR kit, and the method comprises the following steps: 1) specifically performing PCR amplification on the monkeypox virus and the monkey B virus; and 2) generating a melting curve after the amplification is completed, so as to distinguish the monkeypox virus and the monkey B virus by using the difference between the melting curve Tm values. The application has the characteristics of being capable of rapidly and accurately detecting the monkeypox virus and the monkey B virus simultaneously.

The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have neutralizing or cross-neutralizing activity against poxvirus, in particular against monkeypox virus, vaccinia virus and cowpox virus. The invention relates also to the use of such monoclonal antibodies or antigen binding portion thereof in therapy, prophylaxis and diagnosis of poxvirus, in particular monkeypox virus, vaccinia virus and cowpox virus dependent diseases.

The application discloses primers and fluorescent probes for detection of monkeypox virus. The nucleic acid sequence of the primers comprises sequences shown in SEQ ID NO. 1-SEQ ID NO. 4; and the nucleic acid sequence of the fluorescent probes comprises sequences shown in SEQ ID NO. 5-SEQ ID NO. 6. Two pairs of primers and corresponding fluorescent probes are designed creatively, which can specifically detect a new target gene B21R in the monkeypox virus DNA, and the target site has conservation and specificity. In addition, a double fluorescent PCR method is established, which can further improve the specificity and accuracy of the monkeypox virus detection.

This application relates to humanized monoclonal antibodies against monkeypox virus and their applications. By screening humanized mouse anti-B6R specific binding memory B cells with fully human antibodies, humanized high-neutralizing activity monkeypox virus antibodies B6R-16A1, B6R-21G7, B6R-22D12, B6R-22F9, and B6R-22H1 were obtained. These antibodies have the characteristics of strong binding ability to monkeypox virus, good in vitro neutralization, high affinity, and in vivo protective effect.

This invention discloses a primer-probe combination for detecting monkeypox virus and its branches, and its application, belonging to the field of virus detection technology. Based on the monkeypox virus genome, this invention successfully designed a set of specific primers and probes capable of detecting monkeypox virus and its branches. Based on these primers and probes, this invention establishes a method for detecting monkeypox virus and its branches using multiplex real-time fluorescent PCR. This method can accurately detect the pathogen in clinical monkeypox virus samples, and the detection results are completely consistent with the typing results determined by genome sequencing. The detection method provided by this invention is low-cost, effectively reduces labor and time costs, and improves detection efficiency, showing promising application prospects in laboratory diagnosis, on-site detection, and health assessment of viruses.

The invention discloses a monoclonal antibody MPXV-mAb 975 and an application of the monoclonal antibody MPXV-mAb 981 in preparation of a medicine for preventing and treating a monkey pox virus. According to the invention, an established plaque phenotype experiment is utilized to evaluate the neutralizing activity of the two antibodies to the VACV, and the result shows that the two monoclonal antibodies can inhibit the propagation of the VACV between cells; effects of ADCC and ADCP mediated by the two antibodies are detected, and through a reporter gene experiment, the two antibodies show potential ADCC and ADCP activity; animal model data shows that both the two antibodies can protect CAST / EiJ mice and rhesus monkeys, monkey pox virus loads in different tissues and organs of the mice are remarkably reduced, and the number of acnes on the skin of the rhesus monkeys is reduced. The invention proves that the two monoclonal antibodies have in-vivo and in-vitro protection effects, can be used as effective prevention and treatment medicines for monkey pox virus infection, and provide candidate antibody preparations for clinical treatment of monkey pox virus infection.

The invention belongs to the field of biological medicine, and particularly relates to application of Thaflavanin-3 '-Gallate or NAD < + > in preparation of a product for preventing or treating monkey pox virus infection. The invention finds that the protein OPG188 of the monkey pox virus can significantly inhibit the natural immune process of the monkey pox virus, compounds Thaflavanin-3 '-Gallate and NAD + which have the highest affinity with the OPG188 are screened out through molecular virtual docking, and the action effects of the compounds are verified through cell experiments and molecular experiments, which indicates that the Thaflavanin-3'-Gallate and NAD + have the effect of inhibiting the replication of the monkey pox virus. The compound can be used for preparing medicines for resisting monkey pox virus infection.

The present application relates to monkeypox virus human monoclonal antibody and its application, through screening human antibody humanization mouse anti A29L specific binding memory B cell, the human source high neutralization activity monkeypox virus antibody A29L-1B3, A29L-1B2, A29L-1A5 and A29L-1A2 obtained, have the characteristics such as strong monkeypox virus binding ability, good in-vitro neutralization, affinity, have in-vivo protective effect, and are completely different from the monkeypox virus antibody sequence reported, provide the product for the detection and neutralization of monkeypox virus, and provide the possibility for providing the monkeypox virus product with in-vivo protective effect.

Based on a monkey pox virus immunodiagnosis technology based on up-conversion and long-afterglow nanoparticles, the preparation method comprises the following steps: preparing the long-afterglow and up-conversion nanoparticles by adopting a hydrothermal method and a solvothermal method respectively, and constructing the antibody-modified UCNP and PLNP nano probe by utilizing an EDC-NHS cross-linking system after carboxylation modification. The two nanoprobes and an antigen form an immune complex in a double antibody sandwich mode, the UCNPs is excited to emit light at the wavelength of 980 nm, the UCNPs and the PLNPs generate an LRET effect, an obvious signal peak is detected at the wavelength of 700 nm, and the fluorescence signal intensity is in direct proportion to the antigen content. The detection technology is portable and high in sensitivity, the detection limit is as low as the pg / ml level, and the monkey pox virus antigen standard substance can be detected in the range of 1 mg / ml to 1 ng / ml. According to the immunodetection technology provided by the invention, the detection of various pathogens can be realized by replacing antibody combinations aiming at different antigen epitopes, and the application potential in the aspect of infectious disease diagnosis is huge.